460 Studies Now Enrolling
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohns Disease
A study for patients with Crohn's Disease using study drug Mongersen
| Sponsor: | Celgene |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ6925 |
| U.S. Govt. ID: | NCT02641392 |
| Contact: | Simon Lichtiger: 212-305-1021 / sl3687@cumc.columbia.edu |
Additional Study Information:
The purpose of this clinical research study is to test the effects of an investigational (being tested) study medication, GED-0301, in order to find out if GED-0301 can or cannot improve the symptoms of Crohns disease. The study will test 2 doses of GED-0301 compared to placebo. The placebo is a dummy pill that contains no study medication (or GED-0301), but looks exactly like the study medication tablet. This study will test how well your body tolerates GED- 0301 and the effect that GED-0301 has on the symptoms of your Crohns disease. This is a phase 3 study, and it means that the investigational study medication has been tested for safety and is now being tested in a larger number of patients.
This study is closed
